This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Access to Blue Board comments is restricted for non-members. Click the outsourcer name to view the Blue Board record and see options for gaining access to this information.
English to Spanish: Finance sample General field: Bus/Financial Detailed field: Finance (general)
Source text - English The Funding Case
The Peak Investment requirement for the Funding Case was based on the Development Plan that was approved by the JV Board on 17 March 2014. The Funding Case was used as the basis to structure the external debt facilities and the JV equity contributions required to complete the project. The external debt facilities were approved by the JV Board on 10 July 2014. The table below highlights the Peak Investment requirement for the Funding Case.
In addition to the Development Plan capital costs, the Funding Case included additional costs associated with acquisition, financing charges, commissioning and ramp up costs that would be required prior to reaching commercial levels of production. (This is illustrated in Appendix B, the Funding Case assumed that Las Bambas would be cash flow positive from March 2016).
The Development Plan
A key component of the Funding Case was the Development Plan, which refers to the Capital Cost to Mechanical Completion. This was estimated at USD 7,056M based on achieving Mechanical Completion by 30th October 2015. The P50 Project Budget and Project Forecast is summarised below for comparative purposes (refer to section 3 and 4 for further details).
Note, for forecast Peak Investment, only USD 7,252M of the total Project Forecast of USD 7,332 USD will require funding up until June 2016, the remaining USD 80M will be funded by cash flow generated through the ramp –up phase.
Asset Capitalisation
Upon completion of the Project, the Asset Register will be capitalised. Asset Capitalisation should not be confused with the Development Plan capital cost as this is not a ‘like for like’ comparison.
Translation - Spanish Caso de Financiamiento
El requerimiento máximo de inversión en el caso de financiamiento fue basado en el plan de desarrollo aprobado por la Junta de Empresa Conjunta el 17 de marzo del 2014. El caso de financiamiento fue usado como base estructural para las facilidades de deuda externa y las contribuciones de capital de Empresa Conjunta necesarias para finalizar el proyecto. Las facilidades de deuda externa fueron aprobadas por la Junta de Empresa Conjunta el 10 de julio del 2014. La tabla en la parte inferior muestra el requerimiento máximo de inversión en el caso de financiamiento.
Además de los costos de capital del plan de desarrollo, el caso de financiamiento debe incluir costos adicionales asociados con la adquisición, tasas de financiamiento, puesta en marcha y aumento de los costos, que deberían ser requeridos previos a alcanzar niveles de producción comerciales. (Esto se muestra en el anexo B, en el caso de financiamiento se prevé que Las Bambas generará un flujo de fondos positivo desde marzo del 2016).
Plan de Desarrollo
Un punto clave en el plan de financiamiento fue el plan de desarrollo, el cual se refiere al costo de capital para la terminación mecánica. Esto fue previsto en 7,056 millones de dólares para lograr la terminación mecánica el 30 de octubre del 2015. El presupuesto del proyecto P50 y las previsiones del proyecto están resumidos en la parte inferior por motivos comparativos (referirse a la sección 3 y 4 para mayores detalles).
Nota, para la previsión del máximo de inversión, solamente 7,252 millones del total de la previsión del proyecto que fue de 7,332 millones serán requeridos para financiamiento hasta junio del 2016, los 80 millones restantes serán para el flujo de fondos generados a través de la puesta en marcha.
Capitalización de Activos
Al terminar el proyecto, el registro de activos será capitalizado. La capitalización de activos no debe confundirse con los costos de capital del plan de desarrollo, ya que no es una comparación igual.
English to Spanish: Medical sample General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - English A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus
This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive.
Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.
Inclusion Criteria:
• Male or female subjects, age 20 to 75 years, inclusive with type 2 diabetes mellitus.
• At Visit 2/Period 1/Day 1, subjects will have been treated for their diabetes by metformin (≥1000 mg/day; any type and regimen), metformin and a DPP-4 inhibitor ( Dipeptidyl-Peptidase)-4), metformin and an SGLT-2 (Sodium-glucose co-transporter 2) inhibitor, metformin and TZD (Thiazolidinediones), or metformin and sulfonylurea. Subjects will have been on a stable regimen of metformin (defined as the same metformin dose and type) and other treatments for at least 8 weeks prior to Visit 2/Period 1/Day 1.
• Hemoglobin A1c (HbA1c) between ≥7.5 and ≤10.5% at Screening.
Exclusion Criteria:
• Usage of anti-diabetic agents other than metformin, sulfonylurea, SGLT-2 inhibitors, TZD, or DPP-4 inhibitors within 6 weeks prior to Visit 2/Period 1/Day 1.
• Fasting serum glucose >300 mg/dL at Screening; a single repeat test is allowable.
• Laboratory abnormalities at Screening including:
1. C-peptide < 1.0 ng/mL;
2. A bnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X (1.5 times) the upper limit of normal.
Translation - Spanish Un estudio sobre el uso de dosis únicas y múltiples de insulina oral o placebo en pacientes con diabetes mellitus tipo 2.
Este es un estudio de cuatro vías (no paralelo) en el que cada paciente recibe tres de los cuatro tratamientos. El estudio reclutará aproximadamente a 30 pacientes adultos con DM2 desde los 20 hasta los 75 años.
Después de un período de selección de 7 a 10 días, los pacientes elegidos ingresarán a una sesión de placebo ciego simple de 3 días. En el día 4, a cada paciente se le asignará de manera aleatoria una secuencia de tratamiento que incluirá tres asignaciones de tratamiento para cada uno de los tres períodos de tratamiento de acuerdo con el esquema de asignación aleatorio.
Criterios de inclusión:
• Pacientes masculinos o femeninos, desde los 20 hasta los 75 años con diabetes mellitus tipo 2.
• En la Visita 2/Período 1/Día 1, los pacientes habrán recibido tratamiento para la diabetes con metformina (≥1000 mg/día; cualquier tipo y régimen), metformina y un inhibidor de la DPP-4 (dipeptidil-peptidasa-4), metformina y un inhibidor de SGLT-2 (cotransportador de sodio-glucosa 2), metformina y TZD (tiazolidinedionas), o metformina y sulfonilurea. Los pacientes habrán estado en un régimen estable de metformina (definida como la misma dosis y tipo de metformina) y otros tratamientos durante al menos 8 semanas previo a la Visita 2/Período 1/Día 1.
• Hemoglobina A1c (HbA1c) entre ≥7.5 y ≤10.5% en la selección.
Criterios de exclusión:
• Uso de agentes antidiabéticos distintos de la metformina, sulfonilurea, inhibidores de SGLT-2, TZD o inhibidores de DPP-4 dentro de las 6 semanas previo a la Visita 2/Período 1/Día 1.
• Glucemia en ayunas>300 mg/dl en la selección; una sola prueba de repetición está permitida.
• Anormalidades de laboratorio en la selección que incluyen:
1. Péptido C1,5X (1,5 veces) el límite superior de lo normal.
More
Less
Translation education
Other - Complejo Educativo Rio Zarco
Experience
Years of experience: 4. Registered at ProZ.com: Nov 2018. Became a member: Jun 2019.
CafeTran Espresso, MateCat, memoQ, MemSource Cloud, Microsoft Excel, Microsoft Word, OmegaT, Smartcat, Trados Studio, XTM
Bio
I am an experienced Spanish translator who offers different linguistic services such as: English to Spanish translation, Spanish voice-over and/or revision of brand or product names. My areas of translation expertise are marketing, education, medicine and finance.
My experience
English to Spanish Translator - Propio Language Services (Freelance)
May 2024 - Present
● Translation of medical and educational documents.
● Translation of content using an online CAT tool.
Spanish Translator - Flix Global Solution (Contract) February 2023 - Present ● Translated 741,341 words in the medical field (health care), 160,756 words in the educational field, 79,700 words in the financial field, 20,700 words in the marketing field and 54,785 in the general field. ● Use MemoQ, Trados and Memsource CAT tools to translate and edit documents.
Spanish Translator - NaTakallam (Contract) June 2019 - May 2022 ● Translated more than 100,000 words in the areas of education, finance, and marketing. ● Use of CAT tools to streamline the translation, editing, and proofreading process. ● Helping to break down language barriers by translating resources and documents for international aid programs. ● Worked on voice-over and transcription projects.
Get in touch and let's have a conversation.
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Keywords: Spanish, finance, medical, marketing, translations, education, English to Spanish, English to Spanish translations, translation services, high-quality translations. See more.Spanish, finance, medical, marketing, translations, education, English to Spanish, English to Spanish translations, translation services, high-quality translations, translator, Spanish translator, English to Spanish medical translator, English to Spanish financial translator, English to Spanish marketing translator, high quality Spanish translations, Spanish translation services, Spanish translations, English to Spanish translator, English to Spanish freelance translator, Spanish freelancer, Spanish freelance translator. See less.
Expertise